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The interior of the eye, or uvea, is a site of immune privilege where certain immune
responses are attenuated or completely excluded to protect non-regenerating tissues
essential for vision. One consequence of this immunoregulation is compromised immune
mediated elimination of intraocular tumors. For example, certain murine tumor cell lines
which are rejected by host immune responses when transplanted in the skin grow
progressively when placed in the anterior chamber (a.c.) of the eye. Progressive ocular
tumor growth occurs despite induction of tumor-specific CD8+ T cell responses capable
of eliminating a subsequent tumor challenge in the skin or opposite eye. Why these CD8+
T effectors fail to eliminate established ocular tumors is not known. It is well appreciated
that growth of tumors in the a.c. induces the generation of immunosuppressive CD8+
T regulatory (Treg) cells. However, the contribution of CD8+ Treg in ocular tumor
progression remains unclear. Several studies indicate that these CD8+ Treg target
responding CD4+ T cells to inhibit their induction of macrophage-dependent delayed
type hypersensitivity (DTH) responses to tumor antigens (Ags). However, induction of
tumor-specific CD4+ T cell responses does not assure intraocular tumor elimination. This
review is focused on how CD8+ Treg could influence the tumoricidal activity of ocular
tumor-specific CD8 T effector cells.+
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INTRODUCTION
The concept of immune privilege was first advanced in the
1940s by the Nobel laureate Sir Peter Medawar. While study-
ing tissue transplantation he observed that foreign skin grafts
which were normally rejected when transplanted subcutaneously
(s.c.), persisted sometimes indefinitely when transplanted into
other sites that he termed “immune privileged” (Medawar, 1948).
One immune privileged site was the anterior chamber (a.c.) of
the eye, the aqueous humor (AqH) filled cavity located directly
below the cornea and above the lens (Figure 1). As the a.c.
is separated by a blood–AqH barrier and lacks demonstrable
afferent lymphatic drainage, ocular immune privilege was orig-
inally explained by sequestration of ocular antigens (Ags) from
the circulating immune system. However, seminal findings by
Kaplan and Streilein in 1977 which demonstrated that anti-
body responses were generated to foreign Ags placed in the a.c.
(Kaplan and Streilein, 1977) clearly showed that the immune
system was not ignorant of ocular Ags. We now know that cer-
tain immune responses are attenuated or completely excluded
from the eye to protect non-regenerating ocular tissues essen-
tial for vision. This ocular immune privilege is maintained by
unique anatomical and biochemical features of the eye along
with the generation of systemic tolerance to ocular Ags which
is mediated by regulatory T cells (Treg). In this review we focus
on how CD8+ Treg generated during intraocular tumor growth
could influence the tumoricidal activity of tumor-specific CD8+
T effector cells.
MECHANISMS OF OCULAR IMMUNE PRIVILEGE
INFLUENCE OF OCULAR ANATOMY ON IMMUNE PRIVILEGE
The absence of afferent lymphatics (Bill, 1977), an avascular
cornea (Patel and Dana, 2009), and tight junctions between vas-
cular endothelial cells in the iris and retina (Crane and Liversidge,
2008) are barriers to the generation and expression of ocu-
lar immune responses. However, these barriers are not absolute
as administration of soluble Ags into the a.c. has been shown
to induce Ag-specific CD8+ (McKenna et al., 2002, 2005) and
CD4+ (Egan et al., 1996; Perez et al., 2000) T cell expansion
in the ipsilateral submandibular lymph nodes (LNs) and spleens
of mice. In addition, activated T cells can enter even a non-
inflamed retina to induce uveitis (Xu et al., 2003). Therefore,
ocular anatomy may increase the threshold for the generation
and expression of ocular immune responses but clearly does not
prevent them.
Ags encountered within the a.c are thought to exit the eye via
the normal drainage of AqH (Bill, 1977) (Figure 1 inset). AqH
is continually generated by the ciliary body, fills the a.c., and
then primarily drains via the trabecular meshwork and Schlem’s
canal directly into the blood stream. A much smaller percentage
of AqH travels by uveal-scleral flow into the cilary muscle and
then traverses the choroid and sclera to be drained by conjunctival
lymphatics (Bill, 1977). As we will discuss in subsequent sec-
tions, the spleen is essential for the generation of Treg which also
contribute to maintaining ocular immune privilege. Therefore,
preferential trafficking of ocular Ags via the bloodstream to the
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FIGURE 1 | Ocular anatomy and drainage. Anterior chamber (AC).
spleen may favor the induction of T cell tolerance. In addition,
antigen presenting cells (APCs) from the iris and ciliary body
have been shown to selectively traffic to the spleen (Wilbanks and
Streilein, 1992).
BIOCHEMICAL BARRIERS TO OCULAR IMMUNE RESPONSES
T cells recognize processed peptides presented on major histo-
compatibility complex (MHC) molecules. In general, peptides
presented by MHC Class I molecules are recognized by CD8+
T cells whereas CD4+ T cells recognize peptides complexed
with MHC Class II molecules (Figures 2A,B). CD8+ T cells dif-
ferentiate into cytotoxic T lymphocytes (CTL) which primarily
eliminate infected or malignant cells by release of lytic gran-
ules although cytokines are also released (Figure 2A) whereas
CD4+ Thelper cells primarily release cytokines to influence
other immune cells. For example, during DTH responses, CD4+
T cells express IFNγ and/or IL-17 which recruits and acti-
vates macrophages and neutrophils to promote inflammation
(Figure 2B). The response is delayed due to the requisite time for
Ag-specific T cells to expand in draining LN and then migrate to
the site of Ag exposure.
Although the majority of cells within the body express MHC
Class I molecules and can be induced to express MHC Class II
molecules by stimulation with interferon gamma (IFNγ), ocular
tissues demonstrate atypical expression of MHC Class I and II.
For example, corneal endothelial cells express very low levels of
MHC Class I which protects these non-regenerating cells from
lysis by CD8+ CTL (Abi-Hanna et al., 1988). Ocular melanocytes
are impaired in expression of MHC Class II which may mitigate
CD4+ T cell mediated inflammation (Radosevich et al., 2004,
2007).
AqH contains soluble immune suppressive molecules includ-
ing cytokines, neuropeptides, and growth factors that have been
shown to inhibit adaptive immune responses. Benezra and Sacks
documented over forty years ago that AqH could inhibit prolif-
eration of naïve T cells following PHA stimulation (Benezra and
Sachs, 1974), and we now know that high concentrations of the
cytokine TGFβ2 in AqH contributed to this suppression (Kaiser
et al., 1989; Cousins et al., 1991). TGFβ2 is normally present in
a latent form within the AqH and elegant work by Masli and
coworkers demonstrated a critical role of thrombospondin-1 in
activation of latent TGFβ2 to preserve ocular immune privilege
(Masli et al., 2006).
Taylor and coworkers have clearly shown that AqH directs
in vitro primed CD4+ T cells away from an IFNγ express-
ing phenotype and toward a TGFβ1 producing Treg type
(Taylor et al., 1997). Factors within AqH including TGFβ2
and alpha-melanocyte stimulating hormone (α-MSH) can alone
generate Treg (Nishida and Taylor, 1999). In combination,
α-MSH increases the frequency of Treg by abrogating the
anti-proliferative effects of TGFβ (Nishida and Taylor, 1999).
Additional factors within AqH that favor Treg generation include
somatostatin which induces α-MSH production in T cells (Taylor
and Yee, 2003) and vasoactive intestinal peptide (VIP) which
inhibits IFNγ production in effector T cells (Taylor et al., 1994).
AqH also contains molecules that inhibit innate immune
responses. For example, high concentrations of ascorbic acid in
AqH have been shown to inhibit myeloperoxidase activity of
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FIGURE 2 | T cell recognition and response. Antigen recognition and response by (A) CD8+ cytolytic T lymphocytes (CTL) and (B) CD4+ T helper cells.
Antigen presenting cell (APC), cluster of differentiation (CD), delayed type hypersensitivity response (DTH), T cell receptor (TCR), major histocompatibility
complex (MHC), and red blood cell (RBC).
neutrophils (Rosenbaum et al., 1985) and macrophage migra-
tion inhibitory factor (MIF) in AqH inhibits NK cell activity
(Apte et al., 1998). AqH-mediated changes to the innate immune
response also influence the adaptive immune response. For exam-
ple, pretreatment of macrophages with TGFβ2 decreased their
expression of CD40 and IL-12 and increased TGFβ1 expression
(Takeuchi et al., 1998). Consequently, CD4+ T cells stimulated
with TGFβ2 treated APC were deviated from IFNγ producing
T cells to TGFβ1 producing Treg (Takeuchi et al., 1998; Keino
et al., 2006b).
The interior of the eye is also lined by a continuous layer of
pigmented epithelial (PE) cells of the iris, ciliary body, and retina
along with the corneal endothelium. All of these ocular tissues
have been shown to induce T cells to become immunosuppressive
Treg in vitro (Sugita et al., 2006, 2008, 2009, 2011). Iris PE cells
best convert CD8+ T cells into Treg via their expression of CD86
which engages CTLA-4 on activated CD8+ T cells (Sugita et al.,
2008). In contrast, retinal PE cells and corneal endothelial cells
express CTLA-2α which better converts CD4+ T cells into Tregs
by decreasing cathepsin-L activity in T cells (Sugita et al., 2008,
2009). Expression of TGFβ1 by CD8+ (Sugita et al., 2008) and
CD4+ Tregs (Sugita et al., 2006) contributes to their immuno-
suppressive activity. In addition, CD8+ Tregs generated by iris
PE express CD86 (Sugita et al., 2006) and the immnosuppressive
molecule programmed death 1 (PD-1) to suppress CTLA-4+ and
PD-1 ligand+ T cell effectors (Sugita et al., 2010).
Cells lining the interior of the eye also express death induc-
ing molecules including CD95/FasL (Griffith et al., 1995a), and
PD-1 ligand (Hori et al., 2006) which can induce apoptosis of
effector T cells expressing CD95/Fas and PD-1 respectively. The
significance of these death-inducing molecules is very appar-
ent in corneal transplantation as corneal allografts deficient in
CD95/FasL (Stuart et al., 1997; Yamagami et al., 1997) or PD-1
ligand (Hori et al., 2006) are rejected with increased frequency.
Apoptotic CD4+ T cells were observed at the allograft junction
of accepted corneas whereas CD4+ T cells accumulated in reject-
ing corneal allografts (Hori et al., 2006) which supported a death
inducing mechanism for these molecules.
Taken together, the above data suggest a model (Figure 3) in
which activated effector T cells are inactivated by their conver-
sion into Treg as they extravasate from blood vessels and cross
epithelial boundaries to enter the eye. Those effectors that escape
this regulation may be converted into Treg by immunosuppres-
sive factors within ocular fluids, like AqH, or induced to undergo
apoptosis by death inducing molecules within the eye. Again,
these barriers to ocular immune responses are not absolute as
intravenous transfer of activated effector CD4+ T cells specific
for ocular Ags can induce either anterior (Lai et al., 1999) or
poster uveitis (Xu et al., 2003). Similarly, Zhou et al. (2012)
recently showed that effector T cells specific for a retinal Ag did
not become Treg when injected into the posterior chamber of
the eye (Zhou et al., 2012). In addition, naïve mice are protected
from an ocular tumor challenge if first infused intravenously
with tumor-specific CD8+ T effectors (Niederkorn and Streilein,
1984). These data clearly indicate that activated effectors can over-
come immunosuppressive mechanisms within the eye. Hence,
these biochemical barriers must primarily raise the threshold of
expression of ocular immune responses.
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FIGURE 3 | Mechanisms of T cell inactivation within the anterior chamber.
Table 1 | Transplantable intraocular tumor models.
Tumor Tumor origin Recipient Antigens on Intraocular Skin tumor References
cell line mouse strain tumor tumor growth tumor growth
P815 DBA/2 Balb/C Minor MHC Progressive Rejection Niederkorn et al., 1981
P815 DBA/2 C57Bl/6 Minor + Major MHC Rejection Rejection Niederkorn et al., 1981
B16F10 C57Bl/6 A/J Minor + Tumor Ag Progressive Rejection Niederkorn and Streilein, 1983b
B16F10 C57Bl/6 C57Bl/6 Tumor Ag Progressive Progressive Niederkorn, 1984
E.G7-OVA C57Bl/6 C57Bl/6 Ovalbumin Progressive Rejection McKenna and Kapp, 2006
Ad5E1 C57Bl/6 C57Bl/6 Adenovirus Rejection Rejection Schurmans et al., 2001
UV-5C25 C57Bl/6 C57Bl/6 Tumor Ag Rejection Rejection Knisely et al., 1987
P91 DBA/2 DBA/2 Tumor Ag Rejection Rejection Knisely et al., 1987
ANTERIOR CHAMBER ASSOCIATED IMMUNE DEVIATION (ACAID)
One consequence of stringent control of ocular immune
responses is compromised immune mediated elimination of
intraocular tumors. For example, certain murine tumor cell lines
(Table 1) that were rejected when transplanted in the skin grew
progressively when placed in the a.c. of the eye. Progressive
growth of these intraocular tumors was not due to a failure to
prime immune responses. Rather, CD8+ CTL (Niederkorn and
Streilein, 1983a; Ksander and Streilein, 1989) and cytotoxic anti-
body responses (Niederkorn and Streilein, 1982a) specific for
tumor Ags were equivalent or greater than those observed in
mice that rejected the same tumors in the skin. However, ocu-
lar tumor growth also generated immunosuppressive CD8+ Treg
that inhibited CD4+ T cell mediated DTH responses to tumor
Ags (Streilein and Niederkorn, 1985). This unique immune
response which was deviated from the conventional immune
response observed when tumors were injected in the skin was
described by the general term a.c. associated immune deviation
or ACAID.
ACAID has been primarily defined by suppression of DTH
responses to Ags that were first encountered in the a.c. and
has been demonstrated using tumors (Niederkorn et al., 1981),
haptenated splenocytes (Waldrep and Kaplan, 1983), viruses
(Ksander and Hendricks, 1987), and soluble Ags (Wilbanks and
Streilein, 1990). The induction of ACAID is a complicated pro-
cess which requires several tissues including the eye (Niederkorn
and Streilein, 1982b), spleen (Streilein and Niederkorn, 1981),
thymus (Wang et al., 1997), and sympathetic nervous system
(Li et al., 2004; Vega et al., 2009). The current paradigm for the
induction of ACAID (Figure 4) suggests that ocular Ags are pro-
cessed by F4/80+macrophages that were influenced by TGFβ2 in
AqH (Wilbanks et al., 1991, 1992; Wilbanks and Streilein, 1991).
These APCs travel from the eye via the bloodstream to the thymus
andmarginal zone of the spleen.Within the thymus CD4−CD8−
NKT cells are generated (Wang et al., 2001) which migrate to the
marginal zone of the spleen via a MIP-2 chemokine gradient cre-
ated by F4/80+ macrophages from the eye (Faunce et al., 2001;
Faunce and Stein-Streilein, 2002). These F4/80+ macrophages
present Ags directly as well as release Ag which is internal-
ized, processed and presented by B cells (D’Orazio et al., 2001).
Coordinate interactions between F4/80+macrophages (Lin et al.,
2005), B cells (D’Orazio et al., 2001), NKT cells (Sonoda et al.,
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FIGURE 4 | Paradigm of CD8+ Treg generation in ACAID.
1999; Sonoda and Stein-Streilein, 2002), and γδ T cells (Skelsey
et al., 2001; Xu and Kapp, 2002) along with production of IL-10
(D’Orazio and Niederkorn, 1998; Sonoda et al., 2001; Ashour and
Niederkorn, 2006) culminates in the generation of CD4+ and
CD8+ Treg which suppress the induction or expression of DTH
responses respectively (Streilein and Niederkorn, 1985; Wilbanks
and Streilein, 1990).
The significance of ACAID in ocular immune privilege is
clearly demonstrated in splenectomized mice in which ACAID is
terminated (Streilein and Niederkorn, 1981). Splenectomy pre-
vents the generation of CD4+ and CD8+ Tregs, restores DTH
responses to ocular Ags, and promotes spontaneous rejection
of immunogenic tumors placed in the a.c. which would other-
wise grow progressively (Streilein andNiederkorn, 1981). Corneal
allografts are also rejected with greater frequency in splenec-
tomized mice (Yamagami and Dana, 2001).
CD8+ Treg
T cells function to both eliminate pathogens and to resolve
immune responses which, if left uncontrolled, would cause
immunopathology and potentially autoimmunity. The seminal
experiments by Sakaguchi in 1995 identified that immunosup-
pressive CD4+ CD25(IL-2Rα)+ T cells protected mice from
autoimmunity mediated by CD4+ CD25– T cells (Sakaguchi
et al., 1995). These CD4+ Treg represented a distinct lineage
generated in the thymus which could be defined by expression
of the transcription factor forkhead box P3 (FoxP3) (Fontenot
et al., 2003). In addition to these “natural Treg,” peripheral CD4+
T cells could also be induced to express FoxP3 and demonstrated
regulatory activity although FoxP3 negative CD4+ T cells have
also been shown to be immunosuppressive (Shevach, 2009).
It is important to note that immunosuppressive activity of
T cells was first described twenty years earlier by Gershon
and Kondo (Gershon and Kondo, 1971) who demonstrated
that T cells could transfer Ag-specific tolerance to naïve mice.
However, their “infectious tolerance” model was mediated by
CD8+ T cells. Like CD4+ Treg, both natural and adaptive
CD8+ Treg have been described. For example, transfer of nat-
ural CD122(common γ-chain receptor)+ CD8+ Treg prevented
autoimmunity normally observed in CD122 deficient mice (Rifa’i
et al., 2004). In addition, certain treatments (Glatiamer acetate
and Fc-ILT3) which mitigate autoimmune conditions are associ-
ated with an expansion of induced CD8+ Treg cells (Tennakoon
et al., 2006; Vlad et al., 2008). With the exception of FoxP3, there
are no well definedmarkers that distinguish CD8+ T effector cells
from CD8+ Treg cells.
IMMUNE RESPONSES TO INTRAOCULAR TUMORS
As mentioned previously, certain tumors transplanted in the a.c.
of the eye grow progressively despite induction of tumor-specific
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CTL (Niederkorn and Streilein, 1983a; Ksander and Streilein,
1989). A simple explanation for this phenomenon is that CD8+
CTL do not accumulate within the eye, either because they fail to
infiltrate ocular tumors or because they undergo apoptosis within
the eye due to ocular expression of death inducing molecules
(Griffith et al., 1995a; Yamagami et al., 1997; Hori et al., 2006).
However, this is clearly not the case as primary uveal melanomas
are often infiltrated by CD8+ T cells (de la Cruz et al., 1990; Durie
et al., 1990; Meecham et al., 1992; Ksander et al., 1998; McKenna
et al., 2009). Similarly, CD8+ T cells accumulated within progres-
sively growing tumors transplanted in the a.c. of mice (Ksander
et al., 1991; Vicetti Miguel et al., 2010), and T cells isolated
from spleens of mice primed to tumor Ags protected naïve mice
from an ocular tumor challenge when transferred intravenously
(Niederkorn and Streilein, 1984). As transferred T cells influ-
enced tumor numbers within the a.c., these data also indicated
that T cells could exert their tumoricidal effector function within
the immune privileged eye at least in some circumstances. These
data also argue against a conversion of CD8+ CTL into CD8+
Treg within the eye.
Progressive growth of tumors in the a.c. fails to gener-
ate CD4+ T cell dependent DTH responses to ocular tumor
Ags (Niederkorn and Streilein, 1983a; Streilein and Niederkorn,
1985), and restoration of these DTH responses has been associ-
ated with rejection of intraocular tumors. For example, splenec-
tomized Balb/C mice spontaneously eliminated P815 tumors
placed in the a.c. and DTH responses to tumor Ags were
restored (Streilein and Niederkorn, 1981). Similarly, P91 tumors
(a P815 variant) induced strong DTH responses when trans-
planted in the a.c. of syngeneic DBA/2 mice and these intraocular
tumors were also rejected (Niederkorn and Meunier, 1985). The
immunopathological features of intraocular P91 tumor rejection
resembled a DTH response as there was neutrophil infiltration,
extensive damage to normal ocular tissues (including destruc-
tion of themicrovasculature), and ischemic bulk necrosis (Knisely
et al., 1987) resulting in ocular atrophy, termed phthsis. While
these data suggested that DTH responses were critical for ocular
tumor elimination, additional experiments showed that adminis-
tration of anti-CD4 antibodies, which abrogated DTH responses
measured in the footpad, did not prevent rejection of intraocular
P91 tumors (Niederkorn et al., 1990). Similarly, we have observed
that phthsical rejection of P815 tumors in splenectomized Balb/C
mice was not influenced by CD4+ T cell depletion (our unpub-
lished observations). In contrast, CD8 T cell depletion resulted
in progressive growth of P815 (our unpublished observation
and P91 tumors in the a.c. of DBA/2 mice (Niederkorn et al.,
1990) although strong P91-specific DTH responses were observed
in the footpad (Niederkorn et al., 1990). These data indicated
that CD4+ T cell mediated DTH responses to tumor Ags were
excluded from the eye. More importantly, CD8+ and not CD4+
T cells were most critical for elimination of intraocular P91, or
P815 tumors by inducing expression of a “DTH like” immune
response within the eye.
The immune suppressive mechanisms that normally exclude
CD4+ T cell mediated DTH responses from the eye have not
been defined. However, CD4+ T cell infiltration of ocular tumors
does not appear to be compromised as Ad5E1 tumors are
spontaneously rejected when placed in the a.c. by a process that
requires CD4+ T cells, macrophages, and IFNγ (Schurmans et al.,
2001; Wang et al., 2003; Boonman et al., 2006; Dace et al.,
2008). Rejection of these ocular tumors is due to direct effects of
IFNγ on tumors as Ad5E1 were also rejected in IFNγ receptor 1
(IFNγR1) deficient mice (Dace et al., 2007). As Ad5E1 tumors do
not express MHC Class II these data suggest a model in which
CD4+ T cells infiltrating ocular tumors express IFNγ only after
engaging tumor Ags complexed with MHC Class II that are pre-
sented by ocular APC, most probably intratumoral macrophages.
The direct effects of IFNγ on Ad5E1 tumors include inhibit-
ing proliferation, and inducing expression of the death inducing
molecule TRAIL-R2 and several anti-angiogenic molecules which
in combination leads to non-phthsical ocular tumor elimination
(Wang et al., 2003; Dace et al., 2007, 2008). Interestingly, Coursey
and coworkers recently identified an Ad5E1 variant (Clone 2.1)
that was rejected in a phthsical manner (Coursey et al., 2011).
Destructive rejection of these tumors required CD4+ T cells and
nitric oxide producing macrophages. TNFα expression was criti-
cal for inducing Ad5E1 tumor death in amanner which promoted
differentiation of tumoricidal macrophages.
INFLUENCE OF Treg CELLS ON INTRAOCULAR TUMOR GROWTH
Administration of tumors into the a.c. of the eye induces CD8+
Tregs which transfer suppression of DTH responses to recipient
mice (Streilein and Niederkorn, 1985). These CD8+ Treg are not
generated in splenectomized mice that reject tumors transplanted
in the a.c. so it is tempting to speculate that they contribute to
progressive intraocular tumor growth. However, it is important
to note that these Treg do not inhibit the generation of sys-
temic CD8+ CTL or antibody responses directed against ocular
tumors (Niederkorn and Streilein, 1983a; Ksander and Streilein,
1989). Therefore, their immunosuppressive effects could only be
at the “efferent” stage of the immune response targeting effec-
tor immune cells within primary ocular tumors. This notion is
somewhat complicated by the observation that mice bearing pro-
gressively growing tumors in one eye reject a subsequent tumor
challenge in the opposite eye or skin− a phenomenon termed
“intracamerally induced concomitant immunity” (Niederkorn
and Streilein, 1983b; McKenna and Kapp, 2006). The induction
of CD8+ Treg and CD8+ CTL occur with similar kinetics requir-
ing at least 7–10 days to develop (Streilein and Niederkorn, 1981;
McKenna and Kapp, 2006). Therefore as the second tumor chal-
lenge occurred at a time when CD8+ Treg would have already
developed these data indicate that Treg do not influence the
tumoricidal activity of immune responses within the microen-
vironment of the subsequent tumor challenge. However, the
requirements for rejection of established primary ocular tumors
could be different from those necessary to reject subsequent
tumor challenges and thus more or less sensitive to immunoregu-
lation. For example, although Ad5E1 tumors are spontaneously
rejected in the a.c. of C57Bl/6 mice by a process that requires
CD4+ T cells, macrophages and IFNγ (Schurmans et al., 2001;
Wang et al., 2003; Boonman et al., 2006; Dace et al., 2007, 2008),
IFNγ deficient mice reject Ad5E1 tumors placed s.c. in the skin
and these mice also reject a subsequent Ad5E1 challenge in the
a.c. (Dace et al., 2008). Hence, IFNγ is required for rejection of
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established Ad5E1 ocular tumors but not for protection from a
subsequent ocular tumor challenge.
Tumor burden is also significantly greater in established ocu-
lar tumors thereby requiring a stronger immune response to
promote tumor elimination which should be more sensitive to
immunoregulation. For example, serum or LN cells from mice
immunized with P815 tumors s.c. protected naïve mice from an
ocular tumor challenge if given 7 days before or at the same time
as tumor administration in the a.c. but not if given four days
after tumor inoculation (Niederkorn and Streilein, 1984). It is
important to note that the kinetics and consequences of rejec-
tion of intraocular tumors by transferred sera or immune cells
were different and significant. Ocular tumors never developed in
mice given immune sera and the eye was preserved (Niederkorn
and Streilein, 1984) suggesting that cytotoxic antibodies imme-
diately eliminated tumors in the a.c. of the eye. In contrast,
mice given immune LN cells developed established intraocular
tumors which were then rejected by a process that caused phthsis
(Niederkorn and Streilein, 1984). These data suggest that T cell
and macrophage dependent DTH responses were involved in
tumor elimination. Therefore, CD8+ Treg could target effector
T cells or macrophages within ocular tumors to inhibit expression
of DTH responses within the eye and as a result promote ocular
tumor growth.
MECHANISMS OF SUPPRESSION BY CD8+ Treg IN ACAID
Characterization of the immune suppressive activity of CD8+
Treg in ACAID has relied entirely on assays that evaluate the
inhibition of DTH responses. Specifically, splenocytes from mice
given Ag in the a.c. have been shown to inhibit DTH responses
when transferred to recipient mice previously immunized with
the same Ag (Streilein and Niederkorn, 1985; Wilbanks and
Streilein, 1990). In addition, splenocytes from mice given Ag in
the a.c. were shown to suppress DTH responses when injected
into the skin along with Ag and responder splenocytes from
mice immunized with the same Ag in adjuvant. In this “local
adoptive transfer assay” (LAT), responder cells alone induced
DTH responses and these responses were not suppressed by naïve
T cells, or splenocytes frommice given Ag s.c. but only by spleno-
cytes from mice given Ag in the a.c. Further experimentation
indicated that the splenic regulatory cell was a CD8+ T Cell
(Wilbanks and Streilein, 1990) and this observation has been
very reproducible in several different laboratories (Griffith et al.,
1996; Nakamura et al., 2003; Cone et al., 2007; Paunicka et al.,
2011).
CD8+ Treg isolated from mice given Ag in the a.c. suppress
DTH responses in an exquisitely specific manner. For example,
splenic CD8+ T cells from mice given bovine serum albumin
(BSA) in the a.c. suppress BSA-specific responder cells but not
OVA-specific responder cells even if both BSA and OVA Ag are
co-injected in the LAT assay to activate BSA-specific CD8+ Treg
(Wilbanks and Streilein, 1990). These data clearly argue against
“linked suppression” in which CD8+Treg target APC that express
both Ags (Kapp et al., 2006, 2007).
The cellular target of CD8+ Tregs and their mechanism
of immune suppression in the DTH response have not been
fully elucidated. However, in a related system in which CD8+
Tregs were generated after intravenous injection of TGFβ2-
treated Ag-pulsed macrophages, these CD8+ Treg inhibited DTH
responses by inducing apoptosis of responder T cells through
a Fas/FasL dependent mechanism (Kosiewicz et al., 2004).
Similarly, Griffith and coworkers recently demonstrated that
CD8+ Treg generated by the administration of HSV-1, or hap-
tenated splenocytes (TNP-SPL) in the a.c. suppressed DTH
responses by an apoptotic mechanism involving TRAIL/DR5
interactions (Griffith et al., 2011). In a third system in which
CD8+ Treg were generated by injection of haptenated soluble
Ag in the a.c., Cone and coworkers also showed that responding
T cells were targeted by CD8+ Treg to suppress DTH responses
(Cone et al., 2009b). Recognition of responding T cells by CD8+
Treg was restricted by Qa-1 and not MHC Class I (Cone et al.,
2009a) which was consistent with the requirement for Qa-1 pre-
sentation of Ags by B cells in the generation of CD8+ Treg in
ACAID (D’Orazio et al., 2001).
CD8+ Treg that recognize T cell receptor (TCR) peptides pre-
sented by Qa-1 have been shown to lyse Vβ3+ CD4+ T cells
which normally expand in mice given the superantigen staphy-
lococcal enterotoxin A (SEA) (Hu et al., 2004). These data suggest
that under certain circumstances CD8+ Treg are primed to TCR
determinants expressed by responding CD4+ T cells. Recognition
of a TCR expressed by CD4+ T cells which expanded to Ags
administered in the a.c. would nicely explain the specificity of
CD8+ Treg in suppression of DTH responses in ACAID. As
previously described, ACAID CD8+ Treg only suppress DTH
responses to the same Ag as was originally delivered in the a.c.
(Wilbanks and Streilein, 1990). Therefore, these data suggest a
model in which CD8+ Treg eliminate responding T cell pop-
ulations by recognizing a unique TCR determinant presented
by Qa-1 on T cells (Figure 5A). In support of this model two
independent laboratories have identified Ag-specific TCR pro-
teins in serum after administration of Ag in the a.c. which
transfer tolerance to naïve recipient mice (Ferguson et al., 1989;
Griffith et al., 1995b; Hadjikouti et al., 1995). In addition, CD8+
Treg which suppress OVA-specific DTH responses can be gen-
erated by injection of the class II restricted peptide OVA323−339
(Kosiewicz and Streilein, 1996) which supports that CD8+ Treg
in ACAID are not restricted by MHC Class I and could indi-
cate that CD8+ Treg recognized a TCR determinant expressed by
responding OVA323−339-specific CD4+ T cells. The inhibition of
DTH responses by CD8+ Treg was also associated with absence
of immune infiltrates at the site of the LAT assay in the skin which
is consistent with elimination of responder T cells (Cone et al.,
2009a).
A significant caveat to this model is that CD8+ Treg were also
generated in CD4+ deficient MHC Class II−/− mice given sol-
uble Ag in the a.c. (Nakamura et al., 2003). Therefore, CD8+
Treg with specificities other than TCR expressed by CD4+ T cells
may also be generated. For example, CD8+OT-I TCR transgenic
T cells which recognize OVA peptide 257–264 complexed with
Class I Kb were induced to become non-lytic CD103+CD8+ Treg
when stimulated with OVA-pulsed-TGFβ2 treated macrophages
(Kezuka and Streilein, 2000; Keino et al., 2006a). These OT-I
Treg were similar to those observed in ACAID in that they sup-
pressed DTH responses in a LAT assay (Kezuka and Streilein,
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FIGURE 5 | Mechanisms of immunosuppression by CD8+ Treg. CD8+ Tregs may inhibit DTH responses by inducing apoptosis of CD4+ T cell effectors or
macrophages (A) or by functionally inactivating these immune populations via TGFb1 expression (B).
2000; Keino et al., 2006a). However, their cellular target may
be APC (macrophages and/or dendritic cells) and not respon-
der CD4+ T cells (Figure 5B) as Kapp and coworkers showed
in a similar system that OT-I Treg reduced expression of the
costimulatory molecule, CD86, on dendritic cells (Kapp et al.,
2006). TGFβ has been shown to reduce costimulatory molecule
expression on APC (Takeuchi et al., 1998) and is required for
the suppressive activity of CD8+ Treg in ACAID (Cone et al.,
2009b; Jiang et al., 2009) which could suggest additional non-
lytic mechanism for inhibiting DTH responses. However, the
suppression of immune responses by non-lytic OT-I CD8+ Treg
does not require TGFβ (Kezuka and Streilein, 2000; Kapp et al.,
2006) indicating that other immunosuppressive mediators may
be involved. It is important to note that the potential contribu-
tion of CD8+ Treg in promoting ocular tumor growth would
require their recognition of non-CD4+ T cells because CD4+
T cells do not contribute to elimination of intraocular P91
or P815 tumors (Niederkorn et al., 1990 and our unpublished
observations). Therefore, CD8+ CTL effectors or intratumoral
macrophages are logical targets of CD8+ Treg in the ocular tumor
microenvironment (Figure 6).
INDIRECT TUMORICIDAL ACTIVITY OF CD8+ T CELLS
CD8+ T cells play a critical role in immunosurveillance of
tumors by recognition of processed peptides presented by MHC
Class I molecules on the tumor cell surface. Through release of
cytotoxic granules containing granzyme B and perforin CD8+
CTL directly lyse tumor cells (Simon et al., 1997). In addition,
CD8+ CTL express IFNγ which can induce apoptosis of certain
tumors (Wall et al., 2003) and/or influence hematopoietic and
non-hematopoietic cells within the tumor microenvironment to
affect tumor growth (Blankenstein, 2005). For example, IFNγ
dependent regression of B16-OVA melanomas transplanted in
the skin by CD8+ OVA-specific OT-I T cell effectors required
IFNγR1 expression by host cells (Schuler and Blankenstein,
2003). An inhibition of tumor angiogenesis preceded tumor
regression in other models of IFNγ mediated rejection of tumors
by CD8+ T cells suggesting that IFNγ targeted vascular endothe-
lial cells, fibroblasts, and/or pro-angiogenic macrophages (Qin
et al., 2003).
IFNγ may also promote tumoricidal activity in other immune
cell populations within the tumor microenvironment. For exam-
ple, regression of established E.G7-OVA skin tumors by CD8+
OT-I CTL effectors required IFNγ but not perforin expression
by transferred T cells (Hollenbaugh et al., 2004; Hollenbaugh
and Dutton, 2006). IFNγR1 and inducible nitric oxide synthase-2
(NOS2) expression in recipient mice were also required for
tumor regression which indicated that CTL-expressed-IFNγ tar-
geted host cells to eliminate skin tumors (Hollenbaugh et al.,
2004; Hollenbaugh and Dutton, 2006). We recently demon-
strated that transferred OT-I CTL induced F4/80+ macrophages
within E.G7-OVA skin tumors to express tumoricidal concen-
trations of nitric oxide (NO) (Vicetti Miguel et al., 2010).
Hence CD8+ T cell elimination of established E.G7-OVA skin
tumors was indirect via their induction of tumoricidal activity
in intratumoral macrophages. In contrast, established intraoc-
ular E.G7-OVA tumors were resistant to OT-I CTL transfer
therapy although CTL infiltrated primary intraocular tumors and
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FIGURE 6 | Potential targets of CD8+ Treg in intraocular tumors.
expressed IFNγ which induced macrophages to express NOS2
protein; the enzyme responsible for NO production. However,
ocular tumor associated macrophages did not produce apprecia-
ble amounts of NO and were not tumoricidal (Vicetti Miguel
et al., 2010). Therefore, factors within the immune privileged
eye normally inhibit NOS2 enzymatic activity in macrophages
which contributes to ocular tumor progression. These data
highlight that the interplay between CD8+ T cells and intra-
tumoral macrophages is critical for elimination of intraocu-
lar tumors and represents a potential target of CD8+ Treg
(Figure 6).
UVEAL MELANOMA
Immune suppressive mechanisms, which maintain ocular
immune privilege, should theoretically decrease immunosurveil-
lance of intraocular malignancies. However, the most common
intraocular tumor, uveal melanoma (UM), is a rare malig-
nancy. The frequency of UM is over 30 times lower than cuta-
neous melanoma (Singh and Topham, 2003; Garbe and Leiter,
2009). One explanation for this paradox is that the expres-
sion of death inducing molecules within the eye limits tumor
outgrowth. For example, tumor necrosis factor (TNF) related
apoptosis inducing ligand (TRAIL) is expressed by tissues lining
the interior of the eye (Lee et al., 2002) and targets trans-
formed cells for apoptosis (Wiley et al., 1995). P815 tumor cells
transduced to express TRAIL receptor DR5 failed to develop
into ocular tumors when injected into the a.c. of the eye of
Balb/C mice (Lee et al., 2002) which supports this notion.
Therefore, the lower frequency of ocular malignancies may be
due to augmented expression of death inducing molecules that
induce apoptosis in transformed cells. However, when trans-
formed cells become resistant to apoptosis several observations
suggest that ocular immune privilege favors tumor growth and
persistence.
Uveal melanoma is unique in that primary tumors with an
“inflammatory phenotype,” characterized by significant infiltra-
tion with CD8+ T cells and CD68+ macrophages, are generally
larger more vascularized tumors which express a genetic profile
indicative of greater risk of liver metastasis (Maat et al., 2008).
These data suggest that tumor-specific ocular immune responses
are somehow converted within the ocular tumor microenviron-
ment to favor tumor growth which is consistent with immuno-
suppression by ocular immune privilege.
CD8+ T cell function may be impaired within primary uveal
melanomas as reduced CD3zeta chain expression, a marker of
T cell dysfunction, was observed in T cells infiltrating ocu-
lar tumors that ultimately metastasized to the liver (Staibano
et al., 2006). In addition, T cells isolated from primary uveal
melanomas were generally non-responsive, proliferating poorly
after stimulation (Ksander et al., 1998). In other malignancies
reduced CD3zeta chain expression correlated with increased fre-
quencies of activated CD11b+ CD15+ granulocytes in the blood
(Schmielau and Finn, 2001; Zea et al., 2005) and we recently
showed that CD11b+ CD15+ granulocytes were increased in a
cohort of patients with primary UMs (McKenna et al., 2009)
suggesting a possible mechanism for CD3zeta chain downmod-
ulation. Although CD8+ T cells within primary UM appear to
proliferate poorly, they still accumulate within primary uveal
melanomas and indirect evidence suggests that they produce
IFNγ. For example, primary UMs with increased numbers of
CD8+ T cells are associated with increased HLA expression (de
Waard-Siebinga et al., 1996) which is known to be influenced by
IFNγ (de Waard-Siebinga et al., 1995). Moreover, in the E.G7-
OVA/C57Bl/6 mouse model of intraocular tumor development
we observed that CD8+ T cells which infiltrated intraocular
tumors expressed IFNγ at levels which were equivalent to those
observed in CD8+ T cells that infiltrated skin tumors (Vicetti
Miguel et al., 2010).
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IFNγmay actually promote immune evasion by ocular tumors
as primary uveal melanoma lines treated with IFNγ expressed
PD-L1 which inhibited T cell function in vitro (Yang et al., 2008).
Similarly, IFNγ rendered uveal melanoma cell lines resistant to
lysis by CD8+ T cells (Hallermalm et al., 2008). In addition,
IFNγ is required for expression of the suppressive activity of
CD8+ Treg in ACAID (Cone et al., 2007; Paunicka et al., 2011).
Therefore, another explanation for primary uveal melanoma
growth despite infiltration by CD8+ T cells is that these CD8+
T cells are not tumoricidal effectors but rather immune suppres-
sive Treg.
As previously described the transcription factor FoxP3 faith-
fully identifies naturally occurring CD4+ Treg in mice and is also
expressed in some induced CD4+ and CD8+ Tregs (Shevach,
2009). Two studies recently evaluated FoxP3 expression on T cells
infiltrating primary uveal melanomas (Lagouros et al., 2009;
Mougiakakos et al., 2010). FoxP3 expression was observed only
in CD4+ T cells and their numbers were generally very low and
correlated with the size of tumors and frequency of CD3+ T cells
(Lagouros et al., 2009). As both tumor size and CD3+ T infiltra-
tion are negative prognostic indicators (Damato et al., 2011), it
is difficult to discern the influence of CD4+ FOXP3+ Treg on
tumor progression. However, the presence of FOXP3+ Treg in
cycloxygenase-2 (COX-2) positive tumors did predict poor sur-
vival of uveal melanoma patients (Mougiakakos et al., 2010). It
is important to note that these studies could not exclude that
infiltrating CD8+ T cells, though FoxP3 negative, were immuno-
suppressive Treg.
Macrophages have also been shown to influence tumor growth
(Mantovani et al., 2002). For example, macrophages stimulated
with IFNγ and LPS, termedM1, demonstrate tumoricidal activity
through expression of reactive oxygen and nitrogen production.
In contrast, macrophages stimulated with IL-4 and IL-13, termed
M2, are not tumoricidal and actually tumor promoting via
expression of angiogenic factors including VEGF. Macrophages
within primary uveal melanomas express CD163 which is a
marker of M2macrophages (Bronkhorst et al., 2010) and primary
UMs heavily infiltrated with macrophages are more vascular-
ized (Makitie et al., 2001). Taken together these data suggest
that ocular tumor associated macrophages may promote tumor
growth by inducing tumor angiogenesis. Therefore, it is pos-
sible that CD8+ Treg may contribute to ocular tumor growth
by maintaining ocular tumor associated macrophages in an M2
phenotype.
CONCLUSIONS
It is very clear that progressive growth of intraocular tumors
generates CD8+ Treg that inhibit CD4+ T cell dependent DTH
responses to tumor Ags. However, as restoration of CD4+ T cell
responses to tumor Ags does not assure ocular tumor elimina-
tion the contribution of CD8+ Treg in ocular tumor progression
remains unclear. Interestingly, rejection of certain tumors trans-
planted into the a.c. of the eye involves a destructive process
resembling a “DTH-like” response that requires CD8+ T cells
and IFNγ. As several observations indicate that T cell production
of IFNγ is not impaired within ocular tumors, CD8+ Treg may
target macrophages in progressively growing ocular tumors to
prevent their expression of inflammatory mediators that promote
DTH responses which destroy the tumor vasculature, and/or
directly kill tumor cells (Figure 6). One challenge to defining
the role of CD8+ Treg in ocular tumor progression is a specific
marker that discerns CD8+ CTL effectors from CD8+ Tregs.
While the selective expression of CD103 on in vitro generated
CD8+ Treg is encouraging (Keino et al., 2006a), in vivo expres-
sion of CD103 by ACAID CD8+ Treg has not been shown. Future
experimentation which compares and contrasts tumor-specific
immune responses in splenectomized mice that do not gener-
ate CD8+ Treg and eliminate tumors placed in the a.c. to mice
with progressively growing intraocular tumors should help to
define potential targets for CD8+ Tregs and may identify novel
molecules expressed by CD8+ Treg.
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